Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
4.52
Nov 17 • 3:58 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
14.24M
Enterprise Value
39.60M
Income
-16.88M
Sales
37.46M
Book/sh
-0.73
Cash/sh
1.34
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
129
IPO
Aug 08, 2006
P/E
-
Forward P/E
-
PEG
-
P/S
0.38
P/B
-
P/C
3.38
P/FCF
-
EV/EBITDA
-
EV/Sales
1.06
Quick Ratio
0.44
Current Ratio
0.55
Debt/Eq
-
LT Debt/Eq
-
Option/Short
No / Yes
EPS (ttm)
-5.38
EPS next Y
-1.02
EPS next Q
-0.75
EPS this Y
-73.65%
EPS next Y
77.30%
EPS next 5Y
-
EPS past 3/5Y
44.07% 8.18%
Sales past 3/5Y
2.23% -2.00%
EPS Y/Y TTM
-43.07%
Sales Y/Y TTM
9.04%
EPS Q/Q
42.31%
Sales Q/Q
2.56%
Insider Own
13.98%
Insider Trans
129.37%
Inst Own
22.04%
Inst Trans
0.15%
ROA
-40.71%
ROE
-502.89%
ROIC
-184.87%
Gross Margin
72.91%
Oper. Margin
-26.74%
Profit Margin
-45.05%
SMA20
-8.99%
SMA50
-5.55%
SMA200
-49.65%
Trades
Shs Outstand
3.15M
Shs Float
2.71M
52W High
17.00 -73.41%
52W Low
2.84 59.14%
Volatility
17.44% 17.46%
ATR (14)
0.76
RSI (14)
45.77
Beta
1.45
Rel Volume
0.00
Avg Volume
36.39K
Volume
0
Perf Week
-22.07%
Perf Month
-8.87%
Perf Quarter
-36.52%
Perf Half Y
-52.17%
Perf YTD
-64.64%
Perf Year
-65.56%
Perf 3Y
-80.18%
Perf 5Y
-96.28%
Perf 10Y
-95.78%
Prev Close
4.52
Price
4.52
Change %
0.00%
Consensus
Buy
Avg. Price Target
$44.75
Implied Upside
+890.0%
Analysts8incl. previous ratings
Rating Distribution8 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 07, 2023Initiated
RILY logoRB. Riley Securities
Buy$4-11.5%
Oct 14, 2021Resumed
RILY logoRB. Riley Securities
Buy$10+121.2%
Sep 17, 2020Initiated
JEF logoJJefferies
Buy$15+231.9%
Sep 01, 2020Initiated
SSVB Leerink
Outperform$15+231.9%
Aug 08, 2017Reiterated
MMaxim Group
Buy$10 → $12+165.5%
Oct 26, 2016Initiated
AAegis Capital
Buy
May 24, 2016Initiated
MMaxim Group
Buy$8+77.0%
Oct 29, 2015Upgrade
WWBB Securities
Speculative Buy → Buy$13 → $13+187.6%
May 12, 2015Reiterated
MMLV & Co
Buy$28 → $21+364.6%
Apr 01, 2015Reiterated
MMLV & Co
Buy$28 → $30+563.7%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chan Phillip P.Chief Executive OfficerSep 15 '26Buy6.003,77422,644100,996Sep 16 05:30 PM
Capponi VincentPresident and COOSep 14 '26Buy6.052,07312,53740,387Sep 16 04:05 PM
Sobel Alan D.DirectorSep 15 '26Buy6.102,50015,2549,887Sep 16 04:05 PM
Chan Phillip P.Chief Executive OfficerSep 04 '26Buy0.35200,00070,0001,944,432Sep 09 04:05 PM
MARIANI PETER JChief Financial OfficerJun 15 '26Buy0.44100,00044,000638,113Jun 16 07:00 AM
Chan Phillip P.Chief Executive OfficerJun 12 '26Buy0.40251,136100,4541,734,099Jun 15 06:24 PM
Chan Phillip P.Chief Executive OfficerJun 15 '26Buy0.4310,3334,4431,744,432Jun 15 06:24 PM
CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin in August 1997 and is headquartered in Princeton, NJ.
Ph.D.Dr. Phillip P. Chan M.D.
President & COOMr. Vincent J. Capponi M.S.
Chief Financial OfficerMr. Peter J. Mariani CPA
FESCDr. Efthymios N. Deliargyris FACC
Executive Vice President of Sales & MarketingDr. Christian Steiner M.D.